Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

Leslie S. Kean, Linda J. Burns, Tzuyung D. Kou, Roxanne Kapikian, Karissa Lozenski, Amelia Langston, John T. Horan, Benjamin Watkins, Muna Qayed, Brandi Bratrude, Kayla Betz, Xiao-Ying Tang, Mei-Jie Zhang, Sean E. Connolly, Martin Polinsky, Brian Gavin, Andres Gomez-Caminero, Marcelo C. Pasquini

Blood (2024) 144 (17): 1834–1845.

https://doi.org/10.1182/blood.2023023660

Published: 2024

Includes: Supplemental data

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Adam Goldman, Emanuel Raschi, Joab Chapman, Bianca D. Santomasso, Marcelo C. Pasquini, Miguel-Angel Perales, Roni Shouval

Blood (2023) 141 (6): 673–677.

https://doi.org/10.1182/blood.2022017386

Published: 2023

Includes: Supplemental data

Journal Articles

Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study

Meera Mohan, Nathaniel Verhagen, Aditya Shreenivas, Sabarinath Radhakrishnan, Binod Dhakal, Saurabh Chhabra, Michael A. Thompson, Marcelo C Pasquini, Anita D'Souza, Mehdi Hamadani, Aniko Szabo, Anai Kothari

Blood (2022) 140 (Supplement 1): 940–941.

https://doi.org/10.1182/blood-2022-165413

Published: 2022

Journal Articles

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Caron A. Jacobson, Sarah Nikiforow, Sairah Ahmed, David B. Miklos, Yi Lin, Matthew A. Lunning, Brian T. Hill, Armin Ghobadi, Harry Miao, Shilpa Shahani, Clare Spooner, Christine Fu, Anik R. Patel, Hairong Xu, Marcelo C Pasquini

Blood (2022) 140 (Supplement 1): 7512–7515.

https://doi.org/10.1182/blood-2022-155603

Published: 2022

Journal Articles

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Blood (2022) 140 (Supplement 1): 4636–4638.

https://doi.org/10.1182/blood-2022-169452

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Molly Tokaz, Helen Baldomero, Andrew J Cowan, Wael Saber, Hildegard T. Greinix, Mickey Koh, Nicolaus Kröger, Mohamad Mohty, Sebastian Galeano, Shinichiro Okamoto, Naeem A. Chaudhri, Amado J Karduss, Fabio Ciceri, Vergilio Rensi Colturato, Selim Corbacioglu, Alaa M. Elhaddad, Lisa Force, Cristobal Augusto Frutos Ortiz, Andres Gomez-De Leon, Nada Hamad, Nelson Hamerschlak, Naya He, Aloysius YL Ho, Xiao-Jun Huang, Benjamin Jacobs, Heeje Kim, Minako Iida, Leslie E. Lehmann, Régis Peffault de Latour, Mary-Elizabeth M. Percival, Walid Rasheed, Kirk R. Schultz, Adriana Seber, Bor-Sheng Ko, Anderson Simione, Alok Srivastava, Jeff Szer, William A. Wood, Yoshihisa Kodera, Arnon Nagler, John A Snowden, Daniel J. Weisdorf, Jakob R. Passweg, Marcelo C Pasquini, Anna Sureda, Yoshiko Atsuta, Mahmoud Aljurf, Dietger Niederwieser, Martina Perdomo

Blood (2022) 140 (Supplement 1): 8146–8149.

https://doi.org/10.1182/blood-2022-158338

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Lindsay Hammons, Shabi Haider, Marcelo C Pasquini, Saurabh Chhabra, Sabarinath Radhakrishnan, Anthony E. Zamora, Meera Mohan, Jing Dong, Siegfried Janz, Anita D'Souza, Parameswaran Hari, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7215–7216.

https://doi.org/10.1182/blood-2022-165483

Published: 2022

Journal Articles

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Stefan K. Barta, Ariela Noy, Marcelo C Pasquini, Naya He, Tiffany Hunt, Carlos Litovich, Uroosa Ibrahim, Robert A. Baiocchi, Richard F. Ambinder

Blood (2022) 140 (Supplement 1): 1847–1848.

https://doi.org/10.1182/blood-2022-165370

Published: 2022

Journal Articles

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Othmane Jadi, Hancong Tang, Kelly Shea Olsen, Steven Vensko, Qianqian Zhu, Yiwen Wang, Christopher A. Haiman, Loreall Pooler, Xin Sheng, Guy Brock, Amy Webb, Marcelo C Pasquini, Philip L. McCarthy, Stephen R. Spellman, Theresa E. Hahn, Benjamin G. Vincent, Paul M. Armistead, Lara E. Sucheston-Campbell

Blood (2022) 140 (Supplement 1): 668–670.

https://doi.org/10.1182/blood-2022-167165

Published: 2022

Journal Articles

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 1584–1587.

https://doi.org/10.1182/blood-2022-158822

Published: 2022

Journal Articles

Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)

Mendel Goldfinger, Zhen-Huan Hu, Aaron P. Rapoport, Tanya Siddiqi, Lazaros J. Lekakis, Marcelo C Pasquini, Shilpa Shahani, Elande Baro, Jin Xie, Qinghua Song, Fang Sun, Hairong Xu, Frederick L. Locke

Blood (2022) 140 (Supplement 1): 9520–9522.

https://doi.org/10.1182/blood-2022-166510

Published: 2022

Journal Articles

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Blood (2022) 140 (Supplement 1): 4472–4474.

https://doi.org/10.1182/blood-2022-167018

Published: 2022

Journal Articles

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Blood (2022) 140 (Supplement 1): 1852–1855.

https://doi.org/10.1182/blood-2022-162421

Published: 2022

Journal Articles

Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Yiwen Wang, Junke Wang, Ezgi Karaesmen, Abbas A. Rizvi, Alyssa I. Clay-Gilmour, Qianqian Zhu, Loreall Pooler, Xin Sheng, Christopher A. Haiman, Amy Webb, Guy Brock, Stephen R. Spellman, Philip L. McCarthy, Marcelo C Pasquini, Theresa E. Hahn, Lara E. Sucheston-Campbell

Blood (2022) 140 (Supplement 1): 10611–10612.

https://doi.org/10.1182/blood-2022-158870

Published: 2022

Journal Articles

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation

Leslie S. Kean, Linda J Burns, Tzuyung Douglas Kou, Christopher Bond, Roxanne Kapikian, Karissa Lozenski, Xiao-Ying Tang, Mei-Jie Zhang, Michael T Hemmer, Sean E Connolly, Martin Polinsky, Andres Gomez, Marcelo C Pasquini

Blood (2022) 140 (Supplement 1): 1373–1375.

https://doi.org/10.1182/blood-2022-157610

Published: 2022

Journal Articles

Improved Overall Survival of Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Following 7/8 HLA-Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of the Center for International Blood and Marrow Transplant Research Database

Leslie S Kean, Linda J Burns, Tzuyung Douglas Kou, Roxanne Kapikian, Xiao-Ying Tang, Mei-Jie Zhang, Michael Hemmer, Sean E Connolly, Martin Polinsky, Brian Gavin, Andres Gomez, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 3912.

https://doi.org/10.1182/blood-2021-150742

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

NARROW

Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Progressive multifocal leukoencephalopathy in patients treated with chimeric antigen receptor T cells

Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study

Real-World Impact of Time from Leukapheresis to Infusion (Vein-to-Vein Time) in Patients with Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel

Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Chimeric Antigen Receptor-T (CAR-T) Cell Therapy Targeting BCMA in Patients with Prior Allogeneic Transplantation (allo-HCT) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies - Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Improved Overall Survival of Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Following 7/8 HLA-Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of the Center for International Blood and Marrow Transplant Research Database

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only